China
June 8, 2023
On June 7, 2023, Qi-Biodesign Biotechnology Company Limited (“Qi-Biodesign”) announced the appointment of Dr. Bei Zhang as the Chief Executive Officer of QIHE Life Sciences.
Founder Team (from left to right: Dr. Bei Zhang , Dr. Caixia Gao, Dr. Kevin Zhao)
Dr. Caixia Gao , co-founder of Qi-Biodesign, representing the company and the board of directors, warmly welcomes the addition of Dr. Bei Zhang as the CEO. As the inaugural CEO of Qi-Biodesign, Dr. Bei Zhang’s joining is a significant milestone for the company, signaling its entry into a new phase of development. With nearly 30 years of research, product development, and management experience in top multinational biotechnology companies, Dr. Bei Zhang has a deep understanding of the global biotechnology industry and its market landscape. She has successfully led the development of genetically modified traits, aligning perfectly with Qi-Biodesign’s business development strategy.Currently, the field of gene editing is rapidly advancing globally, and there is a generally positive regulatory attitude towards the commercialization of gene editing in various countries. Particularly noteworthy is the recent approval of the first plant gene editing safety certificate in our country, along with the implementation of relevant regulatory guidelines. The gene editing industry is now presented with a rare golden opportunity for development. We unanimously believe and have confidence that Dr. Bei Zhang will lead Qi-Biodesign to achieve key strategic breakthroughs in product development and commercial operations.
Ms. Jing Qiang , Managing Partner at APRICOT CAPITAL, expressed that Qi-Biodesign has achieved many remarkable accomplishments in its development so far. As a long-standing partner of Qi-Biodesign, APRICOT CAPITAL recognizes the outstanding professional background and impressive work capabilities of the newly appointed CEO, Dr. Bei Zhang. Her in-depth knowledge of domestic and international markets, product research and development, and international industry layout, along with her experience in enterprise management and operations, not only aligns with the company’s development needs but also injects sustainable development strength into Qi-Biodesign’s core team. APRICOT CAPITAL hopes that under the leadership of Dr. Bei Zhang, Qi-Biodesign will continue to lead the way in the field of gene editing.
Mr. Tianji Zhu, Partner at CD CAPITAL, stated that Dr. Bei Zhang possesses profound industry insights and extensive industrial experience in the field of biotechnology. He believes that her addition will play a crucial role in the development of Qi-Biodesign. Mr. Zhu looks forward to Dr. Bei Zhang fully leveraging Qi-Biodesign’s deep technological expertise and existing advantages in plant gene editing. He expects her to capitalize on the favorable policy environment and focus on developing high-quality products that meet critical market needs, thereby continuously leading the industry’s development.
Dr. Bei Zhang , the newly appointed CEO of Qi-Biodesign, expressed her delight in joining the company as its first CEO. She expressed gratitude for the recognition from the board and the affirmation from the founding team. As an innovative enterprise leading gene editing technology in China, Qi-Biodesign has accumulated profound expertise and enjoys a first-mover advantage in technology research and development. Dr. Zhang emphasized that the work they are engaged in is highly meaningful. She expressed her strong desire to leverage her over twenty years of industry experience and work together with the Qi-Biodesign management team to continuously break new ground in the industrialization of gene editing. Their goal is to create gene editing products that align with national strategies, cater to market demands, and meet consumer needs. Dr. Zhang eagerly anticipates building upon the strong momentum of Qi-Biodesign’s current development and leading the company into a new phase of growth.
About Qi-Biodesign
Qi-Biodesign Biotechnology Company Limited (“Qi-Biodesign”) was established in 2021 by internationally renowned gene editing scientists Dr. Caixia Gao and Dr. Kevin Zhao. It is a high-tech enterprise dedicated to developing self-controlled and innovative precision gene editing technologies. Since its inception, the company has aimed to become a global leader in gene editing technology. Qi-Biodesign is committed to revolutionary breakthroughs in novel gene editing tool enzymes and delivery technologies, aiming to establish a leading position in the field of gene editing innovation.
Topics
Species
